Evidence map›Paper›PMID 37201660›Full record

ArticleBioorganic & medicinal chemistry letters2023

Identification of new hit to lead magmas inhibitors as potential therapeutics for glioblastoma.

Bhaskar C Das, Javier J Lepe, Mohammed Adil Shareef, Naomi Lomeli, Sasmita Das, Daniela A Bota

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bhaskar C DasArnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA; Department of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Javier J LepeDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, USA.
Mohammed Adil ShareefArnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA.
Naomi LomeliDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, USA.
Sasmita DasArnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA.
Daniela A BotaDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, USA; Department of Neurology, School of Medicine, University of California, Irvine, USA; Department of Neurological Surgery, School of Medicine, University of California, Irvine, USA; Chao Family Comprehensive Cancer Center, School of Medicine, University of California, Irvine, USA.
Long Island University · USUniversity of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
NRSA Training CoreTL1TR001415 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, HEAD, ELIZABETH · 2015 to 2023
$4.2M
Development of Novel MetAP2 inhibitors as potential therapeutics for MicrosporidiosisR01AI132614 · NIAID · LONG ISLAND UNIVERSITY BROOKLYN CAMPUS · PI DAS, BHASKAR CHANDRA, WEISS, LOUIS M. · 2018 to 2022
$2.5M
Targeting of Mitochondrial Lon Protease as a Novel Therapy for GlioblastomaR01NS109423 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BOTA, DANIELA ANNENELIE, DAS, BHASKAR CHANDRA · 2020 to 2024
$2.3M
Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol ExposureR21AA027374 · NIAAA · LONG ISLAND UNIVERSITY BROOKLYN CAMPUS · PI DAS, BHASKAR CHANDRA, SAITO, MARIKO · 2019 to 2020
$675k
NCATS NIH HHS TL1 TR001415NCATS NIH HHS UL1 TR001414NCI NIH HHS P30 CA062203NIAAA NIH HHS R21 AA027374NIAID NIH HHS R01 AI132614NINDS NIH HHS R01 NS109423
6 · The paper itself

Abstract

In continuation of our previous efforts for the development of potent small molecules against brain cancer, herein we synthesized seventeen new compounds and tested their anti-gliomapotential against established glioblastoma cell lines, namely, D54MG, U251, and LN-229 as well as patient derived cell lines (DB70 and DB93). Among them, the carboxamide derivatives, BT-851 and BT-892 were found to be the most active leads in comparison to our established hit compound BT#9.The SAR studies of our hit BT#9 compound resulted in the development of two new lead compounds by hit to lead strategy. The detailed biological studies are currently underway. The active compounds could possibly act as template for the future development of newer anti-glioma agents.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaGliomaCell Line, TumorCell ProliferationHumansStructure-Activity RelationshipAntineoplastic AgentsAnticancerAnti-glioma agentsCarboxamidesGlioblastomaHit to leadMagmas proteinOxadiazboroleOxadiazoles

Identifiers

PMID37201660
PMCPMC10506439
OpenAlexW4376878805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.